Cannassure Pitch Deck Teardown: A Public Market Play

Executive Summary and Vision

Slide 1: Title Slide

The deck opens with a clean, professional aesthetic using a purple color palette. It clearly identifies the company as Cannassure Therapeutics Ltd and highlights its public status on the Tel Aviv Stock Exchange with the ticker TASE: CSURE . The date is noted as February 2019. The background imagery of test tubes and lab equipment immediately signals a focus on science and medical standards rather than recreational lifestyle branding.

Slide 3: Our Vision and Mission

This slide establishes the company's high-level goals. The vision is to be a "world-class, trusted developer and provider of top-quality medical grade cannabis products." The mission statement emphasizes a "holistic integrated production system," which is a key theme throughout the deck. It mentions specific infrastructure components: an advanced agritech breeding and cultivation facility, a state-of-the-art extraction facility, and scientifically advanced R&D. The focus is squarely on addressing "unmet medical needs."

Traction and Leadership

Slide 5: Major Activities So Far

This is a high-density traction slide. Key achievements listed include:

In the process of constructing an advanced agritech indoor growing facility and a cutting-edge extraction facility. · Signed distribution agreement with Hadassah Medical . · Granted financial support by the Israel Innovation Authority for innovative extraction methods. · Received initial permits from the Israeli Medical Cannabis Authority (IMCA) for the full lifecycle of cannabis production. · Signed a binding MOU with Cannika Holdings to establish an agritech incubator on the company's campus.

This slide serves to de-risk the investment by showing that the company has already secured the necessary regulatory permissions and strategic partnerships to operate.

Slide 7: Executive Team

Cannassure presents a heavy-hitting leadership team, which is common for Israeli startups looking to project stability and institutional quality. Major General Ido Nehushtan , Chairman of the Board, is a former commander of the Israel Air Force, bringing significant operational and strategic weight. Ran Amir (CEO) brings 15 years of international experience, including a stint as CEO of Solbar. Nir Peles (Founder/VP Biz Dev) has experience with NASDAQ-listed companies like Bluephoenix Solutions and Alcobra Pharma. Dr. Hadile Ounallah-Saad (VP R&D) holds a Ph.D. in Medical Science and has a background in neurodegenerative disorders. The team composition suggests a blend of military-grade operations, public market experience, and deep medical research.

Market Opportunity and Value Chain

Slide 9: Medical Cannabis Opportunity and Global Market Trends

The deck uses a macro-market approach to justify the opportunity. It cites a MarketWatch forecast from September 2018, projecting a $28B global cannabis market by 2024 . The right side of the slide lists trends: increased demand for medical treatments, rising R&D investment, and regulatory reforms. Crucially, it notes that "price reductions of raw cannabis yields" highlight the opportunity for "top-quality extraction," signaling that Cannassure intends to move up the value chain into high-margin processed products rather than just selling raw flower.

Slide 11: Comprehensive Value Chain

This slide illustrates the company's vertical integration strategy across five pillars:

Breeding: Developing unique strains using advanced technology. · Cultivation: A 4,000 sqm facility built to IMC-GAP standards for consistent yields. · Processing: Large-scale production of oils and APIs, aiming for EU-GMP accreditation . · Distribution: Leveraging the Hadassah Medical agreement to reach pharmacies and licensed customers. · R&D: Developing patent-protected, molecular-based products and hosting a technological incubator with Cannika Holdings.

The emphasis here is on control and quality assurance at every stage, which is a significant competitive moat in a regulated medical market.

Technical Capabilities and R&D

Slide 13: Medical Cannabis Extraction and Processing

This slide dives deeper into the technical side of the business. It reiterates the construction of an IMC-GMP approved facility and mentions the "accumulated expertise, know-how and experience of Solbar Group ." The right side of the slide lists lab activities: stability testing, identification of single APIs, and product development led by a scientific team and regulatory advisors. The presence of the Israel Innovation Authority logo reinforces the government-backed nature of their innovation.

Slide 15: Innovative Medical Cannabis Products Development

Cannassure outlines its future product pipeline here. They intend to develop pharma-grade products for oncological gynecology using active plant-sourced cannabinoids. A key piece of intellectual property is mentioned: a proprietary patent application filed by an expert who previously served as the Intellectual Property Team Manager at Teva Pharmaceuticals . This connection to Teva—a global pharmaceutical giant—is a subtle but powerful credibility marker.

Roadmap and Conclusion

Slide 17: Next Steps, Key Milestones 2019

8.2018 and onwards: Extracting cannabis in the analytical lab. · 6.2019: Completion of the extraction and processing facility (IMC-GMP). · 7.2019: Completion of the indoor grow facility (IMC-GAP). · H2/2019: Ready for production and sale of approved medical cannabis oil and APIs.

This timeline gives investors a clear window for when the company expects to transition from a pre-revenue infrastructure project to a commercial entity.

Slide 19: Thank You

The final slide provides contact information for CEO Ran Amir and lists the logos of key partners and stakeholders: Solbar, Israel Innovation Authority, Hadassah Medical, and the Tel Aviv Stock Exchange. It maintains the professional, corporate tone established at the beginning.

What Works in This Deck

The deck is exceptionally strong at projecting institutional credibility . In a sector often plagued by 'green rush' hype, Cannassure uses its public listing status, high-ranking military leadership, and pharmaceutical pedigree to stand out. The focus on vertical integration is a sound strategy for the 2019 era, as it addresses the supply chain volatility and quality control issues that were prevalent in the medical cannabis market at the time. The specific mention of a 4,000 sqm facility and the Hadassah Medical partnership provides tangible evidence of scale and market access.

What Is Missing from This Deck

The most glaring omission is financial data . While the company is public, an investor deck should still provide a snapshot of the current balance sheet, projected revenue for the H2/2019 launch, and the cost structure of their production. There is no mention of the cost per gram of cultivation, which is a standard metric for cannabis companies. Additionally, the competitive landscape is ignored. In 2019, Israel had several major players (like Tikun Olam) and international competitors were eyeing the market. Failing to address how Cannassure wins against these incumbents is a missed opportunity. Finally, there is no specific "Ask" slide in this version of the deck, likely because the company was already public and might have been using this for general investor relations rather than a specific private placement round.

What a Founder Should Copy

Founders in highly regulated industries should emulate Cannassure's regulatory and partnership focus . By highlighting permits from the IMCA and support from the Israel Innovation Authority, they prove they can navigate the bureaucracy that kills many startups. The team slide is also a masterclass in building authority; even if you don't have a Major General, highlighting specific, relevant corporate experience (like the Teva and Solbar connections) is vital. Lastly, the roadmap (Slide 17) is excellent because it ties specific facility completions to regulatory standards (GMP/GAP), showing that the founders understand the technical requirements of their industry.